4 results
To assess the safety of treatment with escalating dosages of VELCADE in combination with ZARNESTRA in subjects with Intermediate-2 or high risk MDS according to the IPSS classification.
Primary objective: To determine the antitumor activity regarding objective response rate (ORR) of tipifarnib in subjects with locally advanced non-resectable or metastatic, relapsed and/or refractory, non-haematological malignancies with HRAS…
The objective of this clinical study is to prove the safety of the CorNeat KPro.
To observe and evaluate the efficacy, of Magic Touch SCB compared to one of the gold standard treatment for native vessel disease, (everolimus-eluting stent, EES).The main OCT subanalysis endpoints are:- Acute mean and minimum lumen cross-sectional…